Mereo Biopharma Group Plc ADR [NASDAQ: MREO] traded at a low on 2025-10-02, posting a 0.00 loss after which it closed the day’ session at $2.05.
The results of the trading session contributed to over 4565711 shares changing hands. Over the past one week, the price volatility of Mereo Biopharma Group Plc ADR stands at 7.20% while the volatility over the past one month is 5.14%.
The market cap for MREO stock reached $325.95 million, with 159.00 million shares outstanding and 131.27 million shares in the current float. Compared to the average trading volume of 2.21M shares, MREO reached a trading volume of 4565711 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Mereo Biopharma Group Plc ADR [MREO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MREO shares is $7.11 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MREO stock is a recommendation set at 1.11. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Mereo Biopharma Group Plc ADR shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 27, 2025. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on December 06, 2024, representing the official price target for Mereo Biopharma Group Plc ADR stock. Previously, the target price had yet another raise to $8, while Robert W. Baird analysts kept a Outperform rating on MREO stock.
The Price to Book ratio for the last quarter was 6.02, with the Price to Cash per share for the same quarter was set at 0.35.
How has MREO stock performed recently?
Mereo Biopharma Group Plc ADR [MREO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.82. With this latest performance, MREO shares gained by 18.50% in over the last four-week period, additionally sinking by -13.50% over the last 6 months – not to mention a drop of -41.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MREO stock in for the last two-week period is set at 67.24, with the RSI for the last a single of trading hit 0.11, and the three-weeks RSI is set at 0.10 for Mereo Biopharma Group Plc ADR [MREO]. The present Moving Average for the last 50 days of trading for this stock 1.75, while it was recorded at 2.01 for the last single week of trading, and 2.42 for the last 200 days.
Mereo Biopharma Group Plc ADR [MREO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Mereo Biopharma Group Plc ADR [MREO] shares currently have an operating margin of -9185.45% and a Gross Margin at -149.54%. Mereo Biopharma Group Plc ADR’s Net Margin is presently recorded at -9855.56%.
Mereo Biopharma Group Plc ADR (MREO) Capital Structure & Debt Analysis
According to recent financial data for Mereo Biopharma Group Plc ADR. ( MREO), the Return on Equity (ROE) stands at -75.08%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -62.81%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Mereo Biopharma Group Plc ADR’s Return on Invested Capital (ROIC) is -92.03%, showcasing its effectiveness in deploying capital for earnings.
Mereo Biopharma Group Plc ADR (MREO) Efficiency & Liquidity Metrics
Based on Mereo Biopharma Group Plc ADR’s (MREO) latest financial statements, the Debt-to-Equity Ratio is 0.01%, indicating its reliance on debt financing relative to shareholder equity.
Mereo Biopharma Group Plc ADR (MREO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Mereo Biopharma Group Plc ADR. (MREO) effectively leverages its workforce, generating an average of -$1385000.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 8.13% and a Quick Ratio of 8.13%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Mereo Biopharma Group Plc ADR [MREO]
With the latest financial reports released by the company, Mereo Biopharma Group Plc ADR posted -0.02/share EPS, while the average EPS was predicted by analysts to be reported at -0.01/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MREO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Mereo Biopharma Group Plc ADR go to 20.63%.
Insider trade positions for Mereo Biopharma Group Plc ADR [MREO]
There are presently around $69.02%, or 69.69%% of MREO stock, in the hands of institutional investors. The top three institutional holders of MREO stocks are: RUBRIC CAPITAL MANAGEMENT LP with ownership of 15.31 million shares, which is approximately 2.1506%. ADAGE CAPITAL PARTNERS GP, L.L.C., holding 11.79 million shares of the stock with an approximate value of $$42.45 million in MREO stocks shares; and ADAGE CAPITAL PARTNERS GP, L.L.C., currently with $$33.42 million in MREO stock with ownership which is approximately 1.3043%.
